問卷

TPIDB > Search Result

Search Result

篩選

List

52Cases

2025-09-01 - 2028-09-01

Phase I/II

Completed
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPK Pathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations
  • Condition/Disease

    Advanced or Metastatic Solid Tumors With RAS/MAPK Pathway Mutations

  • Test Drug

    DCC-3116

Participate Sites
4Sites

Recruiting4Sites

2020-07-01 - 2026-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting8Sites

2020-10-15 - 2026-12-31

Phase I/II

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting7Sites

2023-07-01 - 2031-11-06

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
12Sites

Recruiting12Sites

2023-07-31 - 2029-02-28

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
12Sites

Recruiting12Sites

2024-07-31 - 2031-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2024-08-15 - 2026-12-31

Others

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Not yet recruiting5Sites

Recruiting4Sites

2025-02-28 - 2032-06-30

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
13Sites

Recruiting13Sites

2025-06-01 - 2025-11-03

Phase III

Not yet recruiting
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
11Sites

Recruiting11Sites

2025-06-06 - 2029-12-10

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites